These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 25964383)

  • 21. Increased serum angiotensin-converting enzyme activity and plasma angiotensin II levels during pregnancy and postpartum in the diabetic rat.
    van Dijk DJ; Boner G; Giler S; Erman A
    J Renin Angiotensin Aldosterone Syst; 2001 Sep; 2(3):193-8. PubMed ID: 11881122
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitroxidative stress and rantes levels in hypertensive rats with diabetes.
    Mason RP; Corbalan JJ; Jacob RF; Dawoud H; Malinski T
    J Physiol Pharmacol; 2015 Feb; 66(1):65-72. PubMed ID: 25716966
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes.
    Komers R; Simkova R; Kazdova L; Ruzickova J; Pelikanova T
    J Renin Angiotensin Aldosterone Syst; 2004 Mar; 5(1):33-8. PubMed ID: 15136972
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significant lower VVH7-like immunoreactivity serum level in diabetic patients: evidence for independence from metabolic control and three key enzymes in hemorphin metabolism, cathepsin D, ACE and DPP-IV.
    Feron D; Begu-Le Corroller A; Piot JM; Frelicot C; Vialettes B; Fruitier-Arnaudin I
    Peptides; 2009 Feb; 30(2):256-61. PubMed ID: 19061927
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of enalapril and eprosartan on the renal vascular nitric oxide system in human essential hypertension.
    Delles C; Jacobi J; John S; Fleischmann I; Schmieder RE
    Kidney Int; 2002 Apr; 61(4):1462-8. PubMed ID: 11918753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effect of zinc in vivo and in vitro on the activities of angiotensin converting enzyme and kininase-I in the plasma of rats.
    White CL; Pschorr J; Jacob IC; von Lutterotti N; Dahlheim H
    Biochem Pharmacol; 1986 Aug; 35(15):2489-93. PubMed ID: 3017354
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The higher immunoreactivity to ACE (angiotensin converting enzyme) in patients with type 2 diabetes mellitus than in non-diabetic individuals.
    Nishida S; Nohno T; Hirokawa Y; Matsuki M; Tanaka J; Ichihara K
    Endocr J; 2003 Apr; 50(2):209-13. PubMed ID: 12803241
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy.
    Seki N; Hashimoto N; Suzuki Y; Yagui K; Saito Y
    Diabetes Res Clin Pract; 2006 May; 72(2):135-41. PubMed ID: 16290123
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association between polymorphism of the angiotensin I converting enzyme gene and hypertension in Turkish type II diabetic patients.
    Araz M; Aynacioglu S; Aktaran S; Alasehirli B; Okan V
    Acta Medica (Hradec Kralove); 2001; 44(1):29-32. PubMed ID: 11367888
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Association of insertion/deletion polymorphism in angiotensin-converting enzyme gene with hypertensive type 2 diabetes mellitus].
    Zhou L; Xue YM; Luo R; Gao F
    Di Yi Jun Yi Da Xue Xue Bao; 2002 Sep; 22(9):808-10. PubMed ID: 12297438
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis.
    Knudsen ST; Andersen NH; Poulsen SH; Eiskjaer H; Hansen KW; Helleberg K; Poulsen PL; Mogensen CE
    Am J Hypertens; 2008 Feb; 21(2):172-6. PubMed ID: 18188164
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes.
    Bozkurt O; de Boer A; Grobbee DE; Kroon AA; Schiffers P; de Leeuw P; Klungel OH
    J Renin Angiotensin Aldosterone Syst; 2009 Jun; 10(2):101-8. PubMed ID: 19502258
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The antihypertensive effects of sodium nitrite are not associated with circulating angiotensin converting enzyme inhibition.
    Pinheiro LC; Amaral JH; Ferreira GC; Montenegro MF; Oliveira-Paula GH; Tanus-Santos JE
    Nitric Oxide; 2014 Aug; 40():52-9. PubMed ID: 24878382
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the effects of angiotensin receptor antagonist, angiotensin converting enzyme inhibitor, and their combination on regression of left ventricular hypertrophy of diabetes type 2 patients on recent onset hemodialysis therapy.
    Suzuki H; Kanno Y; Kaneko K; Kaneko M; Kotaki S; Mimura T; Takane H
    Ther Apher Dial; 2004 Aug; 8(4):320-7. PubMed ID: 15274684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin I-converting enzyme (kininase II) in cardiovascular and renal regulations and diseases.
    Costerousse O; Allegrini J; Huang W; Alhenc-Gelas F
    Biol Res; 1998; 31(3):161-7. PubMed ID: 9830503
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of angiotensin converting enzyme DD genotype with hypertension in diabetes.
    Wierzbicki AS; Nimmo L; Feher MD; Cox A; Foxton J; Lant AF
    J Hum Hypertens; 1995 Aug; 9(8):671-3. PubMed ID: 8523387
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renal protection and angiotensin converting enzyme inhibition in microalbuminuric type I and type II diabetic patients.
    Cooper ME
    J Hypertens Suppl; 1996 Dec; 14(6):S11-4. PubMed ID: 9023709
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protective effects of nebivolol and reversal of endothelial dysfunction in diabetes associated with hypertension.
    Georgescu A; Popov D; Dragan E; Dragomir E; Badila E
    Eur J Pharmacol; 2007 Sep; 570(1-3):149-58. PubMed ID: 17612521
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme.
    Agata J; Ura N; Yoshida H; Shinshi Y; Sasaki H; Hyakkoku M; Taniguchi S; Shimamoto K
    Hypertens Res; 2006 Nov; 29(11):865-74. PubMed ID: 17345786
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy.
    Barnett AH; Bain SC; Bouter P; Karlberg B; Madsbad S; Jervell J; Mustonen J;
    N Engl J Med; 2004 Nov; 351(19):1952-61. PubMed ID: 15516696
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.